• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

异基因造血干细胞移植后复发的骨髓纤维化患者的结局：EBMT 慢性恶性肿瘤工作组的回顾性研究。

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.

机构信息

Comprehensive Cancer Centre, Division of Haematology, King's College, London.

Hammersmith Hospital NHS Foundation Trust, London, United Kingdom.

出版信息

Br J Haematol. 2018 Aug;182(3):418-422. doi: 10.1111/bjh.15407. Epub 2018 May 29.

DOI:10.1111/bjh.15407
PMID:29808926
Abstract

Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.

摘要

异基因造血干细胞移植（allo-HSCT）仍然是骨髓纤维化（MF）的唯一根治方法。文献中关于移植后复发的 MF 患者的结果和治疗的信息很少。我们在此报告了 202 例 MF 患者 allo-HSCT 后复发的治疗和结果。

相似文献

1
Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.异基因造血干细胞移植后复发的骨髓纤维化患者的结局：EBMT 慢性恶性肿瘤工作组的回顾性研究。
Br J Haematol. 2018 Aug;182(3):418-422. doi: 10.1111/bjh.15407. Epub 2018 May 29.
2
European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party.代表欧洲血液与骨髓移植学会（EBMT）慢性恶性肿瘤工作组开展的全欧洲骨髓纤维化异基因造血细胞移植实践调查。
Curr Res Transl Med. 2021 Jan;69(1):103267. doi: 10.1016/j.retram.2020.08.003. Epub 2020 Oct 15.
3
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry.异基因造血细胞移植治疗老年骨髓纤维化患者：EBMT 慢性恶性肿瘤工作组和西班牙骨髓纤维化登记处的一项研究。
Am J Hematol. 2021 Oct 1;96(10):1186-1194. doi: 10.1002/ajh.26279. Epub 2021 Jul 8.
4
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party.异基因造血细胞移植治疗骨髓纤维化：EBMT 慢性恶性肿瘤工作组关于移植物失败、移植物功能不良和复发的定义和管理策略建议：最佳实践推荐。
Leukemia. 2021 Sep;35(9):2445-2459. doi: 10.1038/s41375-021-01294-2. Epub 2021 May 26.
5
Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis.骨髓纤维化异基因造血干细胞移植的回顾性研究。
Bone Marrow Transplant. 2011 Apr;46(4):557-61. doi: 10.1038/bmt.2010.276. Epub 2010 Nov 1.
6
Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.非典型慢性髓性白血病患者的异基因干细胞移植：欧洲血液与骨髓移植协会慢性恶性肿瘤工作组的一项回顾性研究
Br J Haematol. 2017 Jun;177(5):759-765. doi: 10.1111/bjh.14619. Epub 2017 Mar 28.
7
Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.异基因造血干细胞移植治疗原发性血小板增多症和真性红细胞增多症后骨髓纤维化。
Intern Med. 2020;59(16):1947-1956. doi: 10.2169/internalmedicine.4375-19. Epub 2020 Aug 15.
8
Allogeneic haematopoietic stem cell transplantation for primary myelofibrosis and myelofibrosis evolved from other myeloproliferative neoplasms.原发性骨髓纤维化及由其他骨髓增殖性肿瘤演变而来的骨髓纤维化的异基因造血干细胞移植。
Curr Opin Hematol. 2015 Mar;22(2):184-90. doi: 10.1097/MOH.0000000000000121.
9
Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.异基因造血细胞移植治疗 CALR 突变型骨髓纤维化患者：来自 EBMT 慢性恶性肿瘤工作组的研究。
Bone Marrow Transplant. 2023 Dec;58(12):1357-1367. doi: 10.1038/s41409-023-02094-1. Epub 2023 Sep 7.
10
Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting.供者淋巴细胞输注和二次移植作为减轻强度移植后复发骨髓纤维化的挽救治疗。
Br J Haematol. 2012 Oct;159(2):172-81. doi: 10.1111/bjh.12013. Epub 2012 Aug 22.

引用本文的文献

1
Optimization of allogeneic hematopoietic cell transplantation for patients with myelofibrosis treated with ruxolitinib: eligibility, best practices, and improving transplant outcomes.芦可替尼治疗的骨髓纤维化患者异基因造血细胞移植的优化：入选标准、最佳实践及改善移植结局
Ann Hematol. 2025 Apr;104(4):2125-2141. doi: 10.1007/s00277-025-06270-9. Epub 2025 Mar 22.
2
Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review.异基因干细胞移植治疗骨髓纤维化和骨髓增生异常综合征：当代综述
Am J Hematol. 2025 Jun;100 Suppl 4(Suppl 4):16-29. doi: 10.1002/ajh.27660. Epub 2025 Mar 13.
3
Myelofibrosis and allogeneic transplantation: critical points and challenges.
骨髓纤维化与异基因移植：关键点与挑战
Front Oncol. 2024 Jun 20;14:1396435. doi: 10.3389/fonc.2024.1396435. eCollection 2024.
4
Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantation.抗 T 淋巴细胞球蛋白可改善亲缘或非亲缘供者移植后骨髓纤维化患者的无移植物抗宿主病和无复发存活率。
Bone Marrow Transplant. 2024 Aug;59(8):1154-1160. doi: 10.1038/s41409-024-02291-6. Epub 2024 May 21.
5
Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation.移植物抗宿主病及其对骨髓纤维化造血干细胞移植后复发的影响。
Bone Marrow Transplant. 2024 Apr;59(4):550-557. doi: 10.1038/s41409-024-02220-7. Epub 2024 Feb 6.
6
Are transplant indications changing for myelofibrosis?骨髓纤维化的移植指征正在发生变化吗？
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):676-681. doi: 10.1182/hematology.2023000453.
7
Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation.造血细胞移植后复发的骨髓纤维化的供体淋巴细胞输注及分子监测
Hemasphere. 2023 Jun 30;7(7):e921. doi: 10.1097/HS9.0000000000000921. eCollection 2023 Jul.
8
Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center.异基因造血干细胞移植治疗原发性骨髓纤维化：单中心 20 年经验。
Balkan Med J. 2023 May 8;40(3):197-204. doi: 10.4274/balkanmedj.galenos.2023.2022-2-32. Epub 2023 Mar 24.
9
Improved donor chimerism in relapse myelofibrosis post allogenic stem cell transplant with azacitidine and oral decitabine-First case report.阿扎胞苷联合口服地西他滨治疗异基因造血干细胞移植后复发的骨髓纤维化，供体嵌合率提高——首例报告
EJHaem. 2022 Nov 16;4(1):269-272. doi: 10.1002/jha2.611. eCollection 2023 Feb.
10
Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy.骨髓增殖性肿瘤的新型疗法：超越JAK抑制剂单药治疗
J Immunother Precis Oncol. 2021 Jun 29;4(3):117-128. doi: 10.36401/JIPO-20-35. eCollection 2021 Aug.